191 related articles for article (PubMed ID: 11496941)
1. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.
Zobrist RH; Schmid B; Feick A; Quan D; Sanders SW
Pharm Res; 2001 Jul; 18(7):1029-34. PubMed ID: 11496941
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system.
Zobrist RH; Quan D; Thomas HM; Stanworth S; Sanders SW
Pharm Res; 2003 Jan; 20(1):103-9. PubMed ID: 12608543
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo.
Mizushima H; Takanaka K; Abe K; Fukazawa I; Ishizuka H
Xenobiotica; 2007 Jan; 37(1):59-73. PubMed ID: 17178634
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G
Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P
J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567
[TBL] [Abstract][Full Text] [Related]
7. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride.
Sathyan G; Chancellor MB; Gupta SK
Br J Clin Pharmacol; 2001 Oct; 52(4):409-17. PubMed ID: 11678784
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats.
Mizushima H; Kinoshita K; Abe K; Ishizuka H; Yamada Y
Biol Pharm Bull; 2007 May; 30(5):955-62. PubMed ID: 17473442
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of oxybutynin in man.
Douchamps J; Derenne F; Stockis A; Gangji D; Juvent M; Herchuelz A
Eur J Clin Pharmacol; 1988; 35(5):515-20. PubMed ID: 3234461
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
Gupta SK; Sathyan G
J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
[TBL] [Abstract][Full Text] [Related]
11. Enantioselective analysis of oxybutynin and N-desethyloxybutynin with application to an in vitro biotransformation study.
da Fonseca P; de Freitas LA; Pinto LF; Pestana CR; Bonato PS
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Nov; 875(1):161-7. PubMed ID: 18514599
[TBL] [Abstract][Full Text] [Related]
12. Oxybutynin topical and transdermal formulations: an update.
Staskin DR; Salvatore S
Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
[TBL] [Abstract][Full Text] [Related]
13. Transdermal oxybutynin: a review.
Shaw GL; Patel HR
Expert Opin Drug Metab Toxicol; 2007 Jun; 3(3):435-9. PubMed ID: 17539749
[TBL] [Abstract][Full Text] [Related]
14. A Population Pharmacokinetic Model of (R)- and (S-) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers.
Kretschmar M; Suleiman AA; Krause P; Albrecht U; Stein R; Rubenwolf P; Fuhr U; Taubert M
J Clin Pharmacol; 2021 Jul; 61(7):961-971. PubMed ID: 33368382
[TBL] [Abstract][Full Text] [Related]
15. Transdermal oxybutynin: for overactive bladder.
Bang LM; Easthope SE; Perry CM
Drugs Aging; 2003; 20(11):857-64. PubMed ID: 12964892
[TBL] [Abstract][Full Text] [Related]
16. Transdermal drug delivery treatment for overactive bladder.
Dmochowski RR; Starkman JS; Davila GW
Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of intravesical and oral oxybutynin chloride.
Massad CA; Kogan BA; Trigo-Rocha FE
J Urol; 1992 Aug; 148(2 Pt 2):595-7. PubMed ID: 1640530
[TBL] [Abstract][Full Text] [Related]
18. Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder.
Schröder A; Levin RM; Kogan BA; Das AK; Kay F; Mahashabde A
Urology; 2000 Dec; 56(6):1063-7. PubMed ID: 11113769
[TBL] [Abstract][Full Text] [Related]
19. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
Davila GW; Daugherty CA; Sanders SW;
J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
[TBL] [Abstract][Full Text] [Related]
20. The effects of external heating on the permeation of oxybutynin through human epidermal membrane.
Mizushima H; Inoue K; Ishizuka H
Biol Pharm Bull; 2007 Mar; 30(3):612-5. PubMed ID: 17329869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
